JonesTrading analyst Soumit Roy reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ:ADAP) on Friday, setting a price target of $15, which is approximately 84.28% above the present share price of $8.14.
Roy expects Adaptimmune Therapeutics to post earnings per share (EPS) of -$0.24 for the third quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Adaptimmune Therapeutics, with an average price target of $12.75.
The analysts price targets range from a high of $17 to a low of $9.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $761 thousand and a net profit of -$29.76 million. The company's market cap is $1.26 billion.
According to TipRanks.com, JonesTrading analyst Soumit Roy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.1% and a 52.03% success rate.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble (NYSE:NE), and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.